Rid­ing an ADC hot streak, a new biotech bets a megaround that a bet­ter ver­sion of those ther­a­pies is­n't a myth

While most biotech star­tups be­gin with a light bulb mo­ment or in-li­censed tech­nol­o­gy, Myth­ic Ther­a­peu­tics’ roots trace back to a din­ing room ta­ble and an emp­ty note­book.

Alex Nichols and Bri­an Fiske shared an of­fice at Flag­ship be­fore they left a few years ago to cre­ate some­thing in­de­pen­dent. They want­ed to iden­ti­fy a mean­ing­ful prob­lem for pa­tients and solve it. Sev­er­al note­books lat­er, they land­ed on a mis­sion: cre­at­ing a safer, more ef­fec­tive an­ti­body-drug con­ju­gate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER